Skip to main content
. Author manuscript; available in PMC: 2022 Apr 14.
Published in final edited form as: Vaccine. 2020 Mar 12;38(16):3261–3270. doi: 10.1016/j.vaccine.2020.02.078

Figure 2.

Figure 2.

Impact of varying vaccination cost and vaccine efficacy on the incremental cost-effectiveness ratio (ICER) of a therapeutic vaccine given to pregnant women to prevent congenital transmission with current transmission estimates (distribution with a median of 5%, range: 4%−6%) from (A) the third-party payer perspective, and (B) the societal perspective. An ICER of 0 indicates that the vaccination strategy would be economically dominant (i.e., provides cost savings and positive health benefits); ICERs >$60,000/disability-adjusted life year (DALY) averted are not shown.